Skip to content

Inspection Record

Biocon Sdn. Bhd. — FDA 483 Findings

US FDAInspected 2022-08-30Published 2025-06-20 4 findingsQuality unit oversightDocumentation and recordsCleaning validationOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Quality unit oversight

Your firm's quality unit's oversight of your GMP manufacturing and laboratory operations is inadequate.

3Cleaning validation

There is a lack of assurance that your cleaning procedures, used for non-product-contact process equipment in the RABS, is validated to prevent contamination, Specifically, A.

4Other quality system

There is lack ofassurance that water and@/@)) sed in the manufacture ofOG rug substance manufacturing processes is suitable for its intended use.

A record as of the US FDA document published on 2025-06-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Biocon Sdn. Bhd. findings history — including this company's other documentsAll US FDA findings US FDA documents, 2025 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.